GE HealthCare Unveils Enhanced LesionID Pro at SNMMI Conference

News
Article

Emphasizing a zero-click experience, the updated LesionID Pro software, to be introduced at the SNMMI conference, reportedly provides AI-powered automated insights into whole-body tumor burden with PET and SPECT imaging.

While manual segmentation of lesions and comparisons of PET and SPECT images would take hours to ascertain whole-body tumor burden, an emerging artificial intelligence (AI)-enabled software may provide significantly enhanced diagnostic efficiency.

The updated LesionID Pro software, which will be introduced by GE HealthCare at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference, features automated zero-click pre-processing of PET and SPECT images.

GE HealthCare Unveils Enhanced LesionID Pro at SNMMI Conference

Powered by enhanced AI algorithms and designed with input from leading theranostics clinicians, the new LesionID Pro software, which reportedly offers automated analysis of whole-body tumor burden, is slated to be introduced at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference. (Image courtesy of GE HealthCare.)

“(Now) physicians can access critical, patient-specific insights — like tumor volume — without needing to spend hours manually segmenting lesions or aligning multiple scans. This not only helps speed up the diagnostic process but also helps clinicians make fast, informed decisions, which are crucial in cancer care,” noted Jean-Luc Procaccini, the president and CEO of molecular Imaging and computed tomography at GE HealthCare.

Powered by enhanced AI algorithms and designed with input from leading theranostics clinicians, the new LesionID Pro offers automated analysis of whole-body tumor burden, according to GE HealthCare and MIM Software, the developers of LesionID Pro.

Procaccini emphasized that the updated LesionID Pro can play a key role in monitoring the effectiveness of treatments.

“Monitoring treatment response is a critical part of theranostics, and LesionID Pro is designed to significantly streamline the process. By automating the pre-processing of imaging data and providing consistent, quantifiable tumor burden statistics, the software enables clinicians to track changes in tumor volume over time with greater accuracy and less effort,” maintained Procaccini. “This consistency is key for evaluating how well a therapy is working and making timely adjustments to treatment plans. Altogether, it supports precise, data-driven care decisions that can directly impact patient outcomes.”

GE HealthCare noted that LesionID Pro with automated pre-click processing is pending 510(k) clearance by the Food and Drug Administration (FDA).

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 3
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 2
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, Part 1
Addressing Cybersecurity Issues in Radiology
Computed Tomography Study Shows Emergence of Silicosis in Engineered Stone Countertop Workers
Related Content
© 2025 MJH Life Sciences

All rights reserved.